18-Methoxycoronardine attenuates nicotine-induced dopamine release and nicotine preferences in rats.
Two studies were conducted to assess, in vivo, potential anti-nicotinic effects of the iboga alkaloid ibogaine and its synthetic congener 18-methoxycoronaridine (18-MC). As previously demonstrated for ibogaine, using microdialysis, pretreatment (19h beforehand) with 18-MC (40 mg/kg, i.p.) significantly attenuated nicotine-induced dopamine release in the nucleus accumbens of awake and freely moving rats. In an oral model of nicotine self-administration, both ibogaine and 18-MC decreased rats' preferences for nicotine for at least 24 h. Acutely, during the first hour after administration, ibogaine depressed responding for water as well as for nicotine; however, during this same time, 18-MC reduced nicotine intake without affecting responding for water. The results suggest that 18-MC might be the prototype of a new treatment for smoking.
Glick
S D
SD
Department of Pharmacology and Neuroscience, Albany Medical College, NY 12208, USA. sglick@ccgateway.amc.edu
Maisonneuve
I M
IM
Visker
K E
KE
Fritz
K A
KA
Bandarage
U K
UK
Kuehne
M E
ME
D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D000704:Analysis of Variance; D000818:Animals; D004192:Discrimination, Psychological / Q000187:drug effects; D004298:Dopamine / Q000378:metabolism*; D006719:Homovanillic Acid / Q000378:metabolism; D007050:Ibogaine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D008297:Male; D009538:Nicotine / Q000378:metabolism*; D011597:Psychomotor Performance / Q000187:drug effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D012646:Self Administration; D012907:Smoking / Q000188:drug therapy
D015102:3,4-Dihydroxyphenylacetic Acid; D007050:Ibogaine; D009538:Nicotine; C103345:18-methoxycoronaridine; D004298:Dopamine; D006719:Homovanillic Acid